Boehringer Ingelheim announced today that the FIBRONEERTM-IPF trial met its primary endpoint, which was the absolute change ...

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.

Boehringer Ingelheim today announced that the FIBRONEER-IPF trial met its primary endpoint, which was the absolute change ...

The Phase III trial evaluating nerandomilast as a treatment for idiopathic pulmonary fibrosis met its primary endpoint.

IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind, ...

Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...

Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...

Boehringer Ingelheim said that it will submit a new drug application for nerandomilast based on the positive results.

The FDA’s clearance could double Kisqali’s breast cancer market. Elsewhere, Novo is exploring new ways to deliver genetic ...

Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the ...

Boehringer Ingelheim pivotal phase-III FIBRONEER-IPF study of nerandomilast meets primary endpoint: Ingelheim, Germany Tuesday, September 17, 2024, 13:00 Hrs [IST] Boehringer Inge ...